BioCryst Pharmaceuticals, Inc. (BCRX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 857.58M |
| Enterprise value | 1.29B |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 2.41 |
| Price/book (mrq) | 56.59 |
| Enterprise value/revenue | 3.90 |
| Enterprise value/EBITDA | -11.12 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.93 |
| 52-week change 3 | -45.34% |
| S&P500 52-week change 3 | 21.08% |
| 52-week high 3 | 9.0700 |
| 52-week low 3 | 4.0300 |
| 50-day moving average 3 | 5.1060 |
| 200-day moving average 3 | 6.0297 |
Share statistics
| Avg vol (3-month) 3 | 3.18M |
| Avg vol (10-day) 3 | 3.46M |
| Shares outstanding 5 | 206.15M |
| Implied shares outstanding 6 | 206.15M |
| Float 8 | 190.88M |
| % held by insiders 1 | 1.22% |
| % held by institutions 1 | 88.01% |
| Shares short (15 Apr 2024) 4 | 34.39M |
| Short ratio (15 Apr 2024) 4 | 9.91 |
| Short % of float (15 Apr 2024) 4 | 18.55% |
| Short % of shares outstanding (15 Apr 2024) 4 | 16.68% |
| Shares short (prior month 15 Mar 2024) 4 | 30.55M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | -68.36% |
| Operating margin (ttm) | -40.41% |
Management effectiveness
| Return on assets (ttm) | -11.57% |
| Return on equity (ttm) | N/A |
Income statement
| Revenue (ttm) | 331.41M |
| Revenue per share (ttm) | 1.72 |
| Quarterly revenue growth (yoy) | 17.40% |
| Gross profit (ttm) | N/A |
| EBITDA | -95.91M |
| Net income avi to common (ttm) | -226.54M |
| Diluted EPS (ttm) | -1.1800 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 388.99M |
| Total cash per share (mrq) | 1.89 |
| Total debt (mrq) | 848.71M |
| Total debt/equity (mrq) | N/A |
| Current ratio (mrq) | 3.31 |
| Book value per share (mrq) | -2.21 |
Cash flow statement
| Operating cash flow (ttm) | -95.14M |
| Levered free cash flow (ttm) | -67.23M |
© 2024 Yahoo. All rights reserved.